Study to Assess the Long-term Safety and Efficacy of Tirabrutinib in Adults With Relapsed/Refractory B-cell Malignancies

Relapsed/Refractory B-cell Malignancies Clinical Trial

Official title:
An Open-label Study to Assess the Long-term Safety and Efficacy of ONO/GS-4059 in Subjects With Relapsed/Refractory B-cell Malignancies

Status Completed

Clinical Trial Summary

The primary objective of this study is to determine the long-term safety and tolerability of tirabrutinib in adults with relapsed/refractory B-cell malignancy who have tolerated and achieved stable disease or improved with tirabrutinib treatment while enrolled in a prior (parent study) tirabrutinib study (NCT01659255). The dosing regimen will be based on the prior dosing regimen from the parent study.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Neoplasms
Relapsed/Refractory B-cell Malignancies

Clinical Trial Details

NCT number	NCT02457559
Study type	Interventional
Source	Gilead Sciences
Contact
Status	Completed
Phase	Phase 1
Start date	September 10, 2015
Completion date	December 30, 2020

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05780034` - A Study of AC676 for the Treatment of Relapsed/Refractory B-Cell Malignancies	Phase 1
Not yet recruiting	`NCT04943016` - CD19 CAR T Cells in Children and Adults With Relapsed or Refractory CD19 Positive B Cell Malignancies	Phase 1
Recruiting	`NCT04689308` - This is a Phase 1 Study of MH048 in Patients With Selected Relapsed/Refractory B-cell Malignancies	Phase 1
Recruiting	`NCT04861779` - A Study of HSK29116 in Adults With Relapsed/Refractory B-cell Malignancies	Phase 1